These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9217577)

  • 21. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Intestinal parasitic infections and leishmaniasis in patients with HIV infection].
    Moreno-Camacho A; López-Vélez R; Muñoz Sanz A; Labarga-Echevarría P
    Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():52-60. PubMed ID: 9859620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients.
    Ribera E; Ocaña I; de Otero J; Cortes E; Gasser I; Pahissa A
    Am J Med; 1996 May; 100(5):496-501. PubMed ID: 8644760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Visceral leishmaniasis in patient with HIV infection].
    Olea P; Pinilla J
    Rev Chilena Infectol; 2013 Apr; 30(2):216-20. PubMed ID: 23677161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Miltefosine in a case of visceral leishmaniasis with HIV co-infection; and rising incidence of this disease in India.
    Thakur CP; Sinha PK; Singh RK; Hassan SM; Narain S
    Trans R Soc Trop Med Hyg; 2000; 94(6):696-7. PubMed ID: 11198660
    [No Abstract]   [Full Text] [Related]  

  • 26. Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases.
    Patel TA; Lockwood DN
    Trop Med Int Health; 2009 Sep; 14(9):1064-70. PubMed ID: 19552658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Leishmaniasis. Basic principles, clinical aspects, diagnosis and therapy].
    Burbach G; May J; Harms G; Bienzle U
    Dtsch Med Wochenschr; 1999 Jan; 124(4):88-93. PubMed ID: 10071606
    [No Abstract]   [Full Text] [Related]  

  • 28. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study.
    Pintado V; Martín-Rabadán P; Rivera ML; Moreno S; Bouza E
    Medicine (Baltimore); 2001 Jan; 80(1):54-73. PubMed ID: 11204503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Control of zoonotic visceral leishmaniasis: is it time to change strategies?
    Tesh RB
    Am J Trop Med Hyg; 1995 Mar; 52(3):287-92. PubMed ID: 7694973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kala Azar and HIV.
    Shahi SK; Ranga S; Khurana SK; Talib VH
    Indian J Pathol Microbiol; 1998 Jul; 41(3):269-70. PubMed ID: 9805846
    [No Abstract]   [Full Text] [Related]  

  • 31. India's ambition to eliminate visceral leishmaniasis.
    Burki T
    BMJ; 2014 Nov; 349():g6671. PubMed ID: 25380595
    [No Abstract]   [Full Text] [Related]  

  • 32. [The first case of visceral leishmaniasis in a patient with HIV infection in Russia].
    Ermak TN; Kravchenko AV; Gruzdev BM; Filippov PG
    Ter Arkh; 1997; 69(11):48-50. PubMed ID: 9483748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical aspects of visceral leishmaniasis in HIV infection.
    Jarvis JN; Lockwood DN
    Curr Opin Infect Dis; 2013 Feb; 26(1):1-9. PubMed ID: 23221770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: a case report and brief review of the literature.
    Collini P; Premchand N; Lockwood D; Greig J
    Ann Trop Med Parasitol; 2009 Jul; 103(5):455-9. PubMed ID: 19583915
    [No Abstract]   [Full Text] [Related]  

  • 35. [Raised tattoos in a human-immunodeficiency-virus-infected patient].
    García-Lázaro M; Villar C; Natera C; Rivero A
    Enferm Infecc Microbiol Clin; 2009 Dec; 27(10):602-4. PubMed ID: 19419796
    [No Abstract]   [Full Text] [Related]  

  • 36. [Visceral leishmaniasis and HIV infection in the HAART era].
    Marques N; Cabral S; Sá R; Coelho F; Oliveira J; Saraiva da Cunha JG; Meliço Silvestre A
    Acta Med Port; 2007; 20(4):291-8. PubMed ID: 18198072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient.
    Boumis E; Chinello P; Della Rocca C; Paglia MG; Proietti MF; Petrosillo N
    Int J STD AIDS; 2006 May; 17(5):351-3. PubMed ID: 16643688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
    Gangneux JP; Marty P
    Sante; 2001; 11(4):257-8. PubMed ID: 11861203
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure--a case report and brief review of the literature.
    Rybniker J; Goede V; Mertens J; Ortmann M; Kulas W; Kochanek M; Benzing T; Arribas JR; Fätkenheuer G
    Int J Infect Dis; 2010 Jun; 14(6):e522-5. PubMed ID: 19726213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
    Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
    Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.